Tags

Type your tag names separated by a space and hit enter

Effect of erythropoietin axotomy-induced apoptosis in rat retinal ganglion cells.
Invest Ophthalmol Vis Sci. 2004 May; 45(5):1514-22.IO

Abstract

PURPOSE

Erythropoietin (EPO) modulates erythropoiesis by inhibiting apoptosis in erythrocyte progenitors. Recently, EPO has been shown to be protective in experimental models of mechanical trauma, neuroinflammation, cerebral and retinal ischemia, and even in a human stroke trial. However, little is known about EPO signal transduction in vivo and the usefulness of EPO in the prevention of the chronic, purely apoptotic neuronal cell death that contributes to vision loss in glaucoma and the progression of neurodegenerative diseases.

METHODS

EPO's effects and signaling in the retinal ganglion cell axotomy paradigm were studied by Western blot analysis and immunohistochemistry, receptor expression was characterized in the retina before and after lesion. EPO was injected into the vitreous body to investigate neuroprotection of axotomized rat RGCs. Moreover, EPO's effects were studied in cultures of immunopurified retinal ganglion cells. Signal-transduction pathways transmitting neuroprotective EPO effects in vivo were characterized by the use of specific kinase inhibitors, immunohistochemistry, and Western blot analysis.

RESULTS

EPO receptors (EPORs) were expressed on RGC somata and dendrites in vivo. EPOR expression did not significantly change after axotomy. Application of EPO prevented death of neurotrophic-factor-deprived immunopurified rat RGCs in vitro, rescued axotomized RGCs in vivo, and prevented caspase-3 activation. EPO-induced Akt phosphorylation and survival-promoting EPO effects were completely abolished by inhibition of PI-3-kinase. EPO neuroprotection followed a bell-shaped dose-response curve in vitro and in vivo, whereas toxic EPO effects were never observed, even at high concentrations.

CONCLUSIONS

These data support a potential role for EPO as a therapeutic molecule against predominantly apoptotic neuronal cell death in the context of glaucoma or neurodegenerative diseases and delineate the PI-3-K/Akt pathway as the predominant mediator of EPO neuroprotection in this in vivo paradigm of neuronal cell death.

Authors+Show Affiliations

Department of Neurology, University of Göttingen, Göttingen, Germany.No affiliation info availableNo affiliation info availableNo affiliation info availableNo affiliation info availableNo affiliation info available

Pub Type(s)

Journal Article

Language

eng

PubMed ID

15111610

Citation

Weishaupt, Jochen H., et al. "Effect of Erythropoietin Axotomy-induced Apoptosis in Rat Retinal Ganglion Cells." Investigative Ophthalmology & Visual Science, vol. 45, no. 5, 2004, pp. 1514-22.
Weishaupt JH, Rohde G, Pölking E, et al. Effect of erythropoietin axotomy-induced apoptosis in rat retinal ganglion cells. Invest Ophthalmol Vis Sci. 2004;45(5):1514-22.
Weishaupt, J. H., Rohde, G., Pölking, E., Siren, A. L., Ehrenreich, H., & Bähr, M. (2004). Effect of erythropoietin axotomy-induced apoptosis in rat retinal ganglion cells. Investigative Ophthalmology & Visual Science, 45(5), 1514-22.
Weishaupt JH, et al. Effect of Erythropoietin Axotomy-induced Apoptosis in Rat Retinal Ganglion Cells. Invest Ophthalmol Vis Sci. 2004;45(5):1514-22. PubMed PMID: 15111610.
* Article titles in AMA citation format should be in sentence-case
TY - JOUR T1 - Effect of erythropoietin axotomy-induced apoptosis in rat retinal ganglion cells. AU - Weishaupt,Jochen H, AU - Rohde,Gundula, AU - Pölking,Esther, AU - Siren,Anna-Leena, AU - Ehrenreich,Hannelore, AU - Bähr,Mathias, PY - 2004/4/28/pubmed PY - 2004/5/28/medline PY - 2004/4/28/entrez SP - 1514 EP - 22 JF - Investigative ophthalmology & visual science JO - Invest Ophthalmol Vis Sci VL - 45 IS - 5 N2 - PURPOSE: Erythropoietin (EPO) modulates erythropoiesis by inhibiting apoptosis in erythrocyte progenitors. Recently, EPO has been shown to be protective in experimental models of mechanical trauma, neuroinflammation, cerebral and retinal ischemia, and even in a human stroke trial. However, little is known about EPO signal transduction in vivo and the usefulness of EPO in the prevention of the chronic, purely apoptotic neuronal cell death that contributes to vision loss in glaucoma and the progression of neurodegenerative diseases. METHODS: EPO's effects and signaling in the retinal ganglion cell axotomy paradigm were studied by Western blot analysis and immunohistochemistry, receptor expression was characterized in the retina before and after lesion. EPO was injected into the vitreous body to investigate neuroprotection of axotomized rat RGCs. Moreover, EPO's effects were studied in cultures of immunopurified retinal ganglion cells. Signal-transduction pathways transmitting neuroprotective EPO effects in vivo were characterized by the use of specific kinase inhibitors, immunohistochemistry, and Western blot analysis. RESULTS: EPO receptors (EPORs) were expressed on RGC somata and dendrites in vivo. EPOR expression did not significantly change after axotomy. Application of EPO prevented death of neurotrophic-factor-deprived immunopurified rat RGCs in vitro, rescued axotomized RGCs in vivo, and prevented caspase-3 activation. EPO-induced Akt phosphorylation and survival-promoting EPO effects were completely abolished by inhibition of PI-3-kinase. EPO neuroprotection followed a bell-shaped dose-response curve in vitro and in vivo, whereas toxic EPO effects were never observed, even at high concentrations. CONCLUSIONS: These data support a potential role for EPO as a therapeutic molecule against predominantly apoptotic neuronal cell death in the context of glaucoma or neurodegenerative diseases and delineate the PI-3-K/Akt pathway as the predominant mediator of EPO neuroprotection in this in vivo paradigm of neuronal cell death. SN - 0146-0404 UR - https://www.unboundmedicine.com/medline/citation/15111610/Effect_of_erythropoietin_axotomy_induced_apoptosis_in_rat_retinal_ganglion_cells_ L2 - https://iovs.arvojournals.org/article.aspx?doi=10.1167/iovs.03-1039 DB - PRIME DP - Unbound Medicine ER -